Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

APARNA TAMIRISA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124273974
CMS profile
6084
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$738.71

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $738.71 36

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

APARNA TAMIRISA

NPI 1124273974 · CMS profile ID 6084

Allopathic & Osteopathic Physicians / Internal Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124273974?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124273974?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124273974?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1124273974?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $738.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $22.2912/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086114456 CMS
AstraZeneca Pharmaceuticals LP $17.1711/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105764354 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.7311/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117882228 CMS
Exact Sciences Corporation $22.0311/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114927619 CMS
AstraZeneca Pharmaceuticals LP $13.0810/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104347182 CMS
Novo Nordisk Inc $23.5110/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097396396 CMS
AstraZeneca Pharmaceuticals LP $15.8809/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105745352 CMS
Dexcom, Inc. $29.1909/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153282554 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.7208/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117882236 CMS
Lilly USA, LLC $24.5808/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136049337 CMS
Otsuka America Pharmaceutical, Inc. $20.1908/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118991524 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5808/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117882234 CMS
Astellas Pharma US Inc $28.3608/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139366391 CMS
GlaxoSmithKline, LLC. $22.5507/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116414565 CMS
Novartis Pharmaceuticals Corporation $20.6507/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087433982 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.6607/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117882230 CMS
Novo Nordisk Inc $20.6107/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096583978 CMS
Exact Sciences Corporation $17.8006/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114927615 CMS
Lilly USA, LLC $20.4106/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136051173 CMS
Lilly USA, LLC $16.0405/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136000283 CMS
Amgen Inc. $19.6205/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117395764 CMS
Inspire Medical Systems, Inc. $15.7405/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148117122 CMS
Exact Sciences Corporation $22.8505/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114927612 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.1205/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086133346 CMS
Novartis Pharmaceuticals Corporation $16.1904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087433976 CMS
Phathom Pharmaceuticals, Inc. $33.7504/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151131817 CMS
Lilly USA, LLC $24.8303/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136051171 CMS
Novo Nordisk Inc $16.8502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097170254 CMS
Lilly USA, LLC $15.9402/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136050253 CMS
Gilead Sciences, Inc. $25.1502/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133764775 CMS
Amgen Inc. $14.5002/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111721211 CMS
Lilly USA, LLC $31.2602/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136050251 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.6802/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117882232 CMS
Otsuka America Pharmaceutical, Inc. $16.3801/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118991522 CMS
AstraZeneca Pharmaceuticals LP $18.7701/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104755084 CMS
Lilly USA, LLC $23.0501/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136053678 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $82.95 5
PY2020 $241.91 14
PY2021 $436.11 29
PY2022 $964.56 53
PY2023 $844.80 53
PY2024 $738.71 36
PY2025 $1,000.48 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $417,693.13 33
PY2024 Principal investigator $337,941.60 29
PY2023 Principal investigator $114,419.07 43
PY2022 Principal investigator $112,985.59 129
PY2021 Principal investigator $135,746.11 40
PY2020 Principal investigator $314,454.61 68
PY2019 Principal investigator $340,052.76 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $675.57 12/23/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692453917
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $303.00 12/20/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629186809
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $303.00 12/20/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187769
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $368.00 12/17/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 629186655
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 12/16/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629186983
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 12/16/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187505
Principal investigator 1 GlaxoSmithKline, LLC. $116.00 12/16/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
POST-AUTHORISATION SAFETY (PAS) OBSERVATIONAL COHORT STUDY TO QUANTIFY No dispute reported 06/30/2026 669974515
Principal investigator 1 AbbVie, Inc. $5,194.38 12/13/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611797
Principal investigator 1 Novo Nordisk AS $24.99 12/06/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688345
Principal investigator 1 Novo Nordisk AS $720.57 12/03/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692453915
Principal investigator 1 AbbVie, Inc. $18,738.84 11/25/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611799
Principal investigator 1 Bausch Health US, LLC $450.00 11/09/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 684366045
Principal investigator 1 Novo Nordisk AS $675.57 10/29/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692453911
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,018.00 10/25/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187079
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,018.00 10/25/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187747
Principal investigator 1 AbbVie, Inc. $432.30 10/24/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611795
Principal investigator 1 AbbVie, Inc. $14,298.21 09/30/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611793
Principal investigator 1 Novo Nordisk AS $2,333.26 09/26/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692453913
Principal investigator 1 Novo Nordisk AS $9.99 08/30/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688355
Principal investigator 1 Novo Nordisk AS $3.66 08/30/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688357
Principal investigator 1 Novo Nordisk AS $10.99 08/30/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688359
Principal investigator 1 Novo Nordisk AS $12.98 08/30/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688361
Principal investigator 1 AbbVie, Inc. $1,925.92 08/29/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611791
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,018.00 08/23/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629186733
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,018.00 08/23/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187247
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,018.00 08/23/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187273
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,485.00 08/14/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629186695
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,485.00 08/14/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187659
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $19.00 08/08/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629186575
Principal investigator 1 Novo Nordisk AS $24.99 08/02/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688353
Principal investigator 1 AbbVie, Inc. $216.15 07/30/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611789
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $368.00 07/17/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 629187549
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 07/17/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187615
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $4,131.70 07/09/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425653
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $4,400.00 07/01/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425637
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $50.00 07/01/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425639
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $450.00 07/01/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425641
Principal investigator 1 AbbVie, Inc. $21,374.44 06/27/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611787
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,210.00 06/17/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629186845
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,210.00 06/17/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187703
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,018.00 06/06/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629186881
Principal investigator 1 AbbVie, Inc. $2,610.76 05/29/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611785
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,373.00 05/16/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629186915
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,659.00 05/16/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187109
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 05/16/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187593
Principal investigator 1 Novo Nordisk AS $3,000.00 05/07/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692453907
Principal investigator 1 Novo Nordisk AS $500.00 05/07/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 692453909
Principal investigator 1 AbbVie, Inc. $1,061.32 04/29/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611781
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $461.00 04/11/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY 94-8862 ph 3 conventional in diab nephropathy No dispute reported 06/30/2026 629187637
Principal investigator 1 AbbVie, Inc. $350.00 04/08/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M12-815 No dispute reported 06/30/2026 647611771
Principal investigator 1 AbbVie, Inc. $690.00 04/08/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M12-815 No dispute reported 06/30/2026 647611773
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $765.90 04/08/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425579
Principal investigator 1 AbbVie, Inc. $1,500.00 04/04/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M12-815 No dispute reported 06/30/2026 647611775
Principal investigator 1 AbbVie, Inc. $1,500.00 04/04/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M12-815 No dispute reported 06/30/2026 647611777
Principal investigator 1 AbbVie, Inc. $1,500.00 04/04/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M12-815 No dispute reported 06/30/2026 647611779
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 04/04/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629186771
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 04/04/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187221
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 04/04/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187571
Principal investigator 1 Novo Nordisk AS $117.78 04/04/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688349
Principal investigator 1 Novo Nordisk AS $75.00 04/03/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688351
Principal investigator 1 AbbVie, Inc. $11,959.20 04/01/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611783
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $9,697.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187015
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187193
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,780.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187329
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $810.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187357
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $500.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187385
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,000.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187413
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,375.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187461
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $728.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187483
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $270.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187527
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $100.00 03/21/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187791
Principal investigator 1 AbbVie, Inc. $53,643.94 03/19/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611765
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $371.00 03/15/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629186615
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $758.00 03/15/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629186949
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $758.00 03/15/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187047
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $641.00 03/15/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187165
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,513.00 03/15/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187681
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $371.00 03/15/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187725
Principal investigator 1 Bausch Health US, LLC $1,042.50 03/07/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 684348887
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,444.50 03/01/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 701425695
Principal investigator 1 AbbVie, Inc. $1,042.76 02/28/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611757
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 02/14/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187813
Principal investigator 1 Novo Nordisk AS $1.70 02/08/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706688347
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $72,289.21 02/05/2019 Non-covered Recipient Entity
Interspond - Houston Center For Clinical Research
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to No dispute reported 06/30/2026 639761893
Principal investigator 1 AbbVie, Inc. $490.00 02/01/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611759
Principal investigator 1 AbbVie, Inc. $1,500.00 02/01/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611761
Principal investigator 1 AbbVie, Inc. $1,120.00 02/01/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611763
Principal investigator 1 AbbVie, Inc. $8,520.47 01/29/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611767
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $542.00 01/15/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187137
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,432.00 01/15/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629187439
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,832.28 01/15/2019 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 52 WEEK STUDY TO DEMONSTRATE THE EFFICACY SAFETY AND TOLERABILITY OF SECUKINUMAB INJECTIONS WITH 2 ML AUTO INJECTORS 300 MG IN ADULT SUBJECTS WITH PLAQUE PSORIASIS No dispute reported 06/30/2026 640717441
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,334.00 01/09/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 629187301
Principal investigator 1 AbbVie, Inc. $16,170.93 01/02/2019 Non-covered Recipient Entity
Houston Center For Clinical Research
M16-283 No dispute reported 06/30/2026 647611769